Objectives: We evaluated the role of these metabolic pathways in RA-FLS proliferation and in autoimmune arthritis in SKG mice. Methods: The expression of glycolysis-or glutaminolysis-related enzymes was evaluated by real-time PCR and Western blotting, and the intracellular metabolites were evaluated by metabolomic analyses. The effects of glucose or glutamine on RA-FLS cell growth were investigated using glucose-or glutamine-free medium. Glutaminase 1 (GLS1) siRNA and the GLS1 inhibitor compound 968 were used to inhibit GLS1 in RA-FLS. Arthritis was induced in SKG mice by zymosan A injection. Compound 968 was used to study the effect of GLS1 inhibition on Zymosan A-injected SKG mice. Ki-67-positive cells were analyzed by immunohistochemistry. Results: GLS1 expression was increased in RA-FLS, and metabolomic analyses revealed that glutamine and glutamate consumption were increased in RA-FLS. RA-FLS proliferation was reduced under glutamine-deprived, but not glucosedeprived conditions. Cell growth of RA-FLS was inhibited by GLS1 siRNA transfection or GLS1 inhibitor treatment. Silencing of GLS1 in RA-FLS did not affect IL-6 or MMP-3 production in supernatants. GLS1 expression in RA-FLS was not affected by pro-inflammatory cytokine stimulation. Compound 968 ameliorated the autoimmune arthritis and decreased the number of Ki-67-positive synovial cells in SKG mice.
FRI0023 ARTESUNATE CAN INHIBIT MIGRATION AND INVASION OF FIBROBLAST-LIKE SYNOVIOCYTES VIA SUPPRESSION OF MATRIX METALLOPROTEINASE 9 IN RHEUMATOID ARTHRITIS PATIENTS
It has also been demonstrated that artesunate may ameliorate the symptoms of arthritis and prevent joint damage in collagen induced arthritis rat, which suggests that artesunate may be used for RA treatment. Recent studies show that RA-FLS is critical for joint destruction in RA because it can migrate and attach to cartilage and bone, and then invade them by secreting proteases such as matrix metalloproteinases (MMP) 9 in RA. However, effects of artesunate on migration and invasion of RA-FLS are poorly understood. Objectives: To investigated the effects of artesunate on migration and invasion of RA-FLS and its underlying mechanism. Methods: Synovial tissues were obtained from active RA patients as well as osteoarthritis (OA) and noninflammatory orthopedic arthropathies (Orth.A) patients and immumohistochemical (IHC) staining were performed for MMP9 expression. FLS isolated from these patients were analyzed for MMP9 exprssion by western blot (WB) and incubated with artesunate at different concentrations (0μM, 20μM, 40μM and 60μM), methotrexate (MTX, 10nM) or hydroxychloroquine (HCQ, 20μM) for 24 hours. Effects of artesunate on migration and invasion capacity were detected by transwell and wound healing assays. MMP9 and PI3K/Akt signal transduction protein expression after artesunate treatment was measured by WB. Results: (1) IHC staining showed that synovial MMP9 expressed in lining and sublining area with intense nuclear and endochylema staining in RA synovium and the percentage of MMP9+ cells was significantly higher in RA (n=32) than that in OA (n=6) or Orth.A (n=6, Figure 1A , B).
(2) Migration and wound healing assays for 12 hours and invasion assay for 24 hours showed that RA-FLS possessed stronger capacity in migration and invasion than OA-FLS or Orth.A-FLS ( Figure 1E, F) . Artesunate inhabits the migration and invasion capacity of RA-FLS in a dose-dependent manner. MTX also has an inhibition effect on the migration and invasion of RA-FLS, but not HCQ ( Figure  2A) . (3) MMP9 expression in RA-FLS was significantly higher than that in OA-FLS or Orth.A-FLS (Figure 1C, D) . 40μM or 60μM artesunate markedly inhibited the expression of MMP9 in RA-FLS by WB ( Figure 2B ). (4) WB analysis showed artesunate suppressed generation of phophso-Akt in a dose-dependent manner which indicated that Akt activity (phophso-Akt/Akt) in 40μM and 60μM artesunate treatment groups were significantly lower than that in untreated group ( Figure 2C ).
Conclusions:
Artesunate could inhibit the migration and invasion capacity of RA-FLS and the expression of MMP9 through suppressing Akt activity.
